



- **Core measures**
 - **CORE6e** - Pain addressed appropriately by second office visit and during most recent office visits
 - **CORE14** - Signed patient consent for chemotherapy
 - **Core 22bb** - Tobacco cessation counseling administered or patient referred in past year
- **Symptom management**
 - **SMT33** - Infertility risk discussed prior to anti-neoplastic treatment with patients of reproductive age
 - **SMT28a** - Aprepitant/Fosaprepitant or Netupitant prescribed with Cycle 1 of low or moderate emetic risk chemotherapy (Lower score better)
 - Carboplatin @ AUC ≥ 4 → Emend is recommended by latest ASCO guidelines
- **End-of-life**
 - **EOL38*** - Pain addressed appropriately
 - **EOL41** - Dyspnea addressed appropriately
 - **EOL44** - Hospice enrollment within 3 days of death (**Lower score better**)
 - **EOL47*** - Hospice enrollment, palliative care referral/services, or documented discussion (combined measure EOL43 or EOL46)
 - **EOL43** - Hospice enrollment or palliative care referral/services
 - **EOL46** - For patients not referred, hospice or palliative care discussed within the last two months of life
 - **EOL48** – Chemotherapy administered within the last two weeks of life (New Measure)
- **Surgical**
 - **GYNONC90g** - Operative report with documentation of residual disease (Optimal/Suboptimal)
- **Chemotherapy**
 - **GYNONC94** - Platinum and taxane administered within 28 days following cytoreduction (or staging surgery) to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or primary peritoneal cancer
- **Test Measures**
 - **GynOnc #1** Days from Debulking surgery to chemotherapy start
 - **GynOnc #2** Patients with ovarian cancer referred to genetic testing/counselling